ArticleAdvances in therapy2026
Safety of Ravulizumab Use in Pregnancy: Insights from a Global Pharmacovigilance Analysis.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06312644 (Observational Study of Ultomiris®), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRavulizumab, a second-generation terminal complement C5 inhibitor (engineered from eculizumab) is approved for the treatment of rare complement-mediated disorders paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). While eculizumab has an established pregnancy safety profile across these indications, data on ravulizumab during pregnancy and lactation remain limited. This analysis evaluated pregnancy-related safety and outcomes following ravulizumab exposure using global post-marketing data.
methodsAll globally reported pregnancy cases with ≥ 1 documented ravulizumab dose were identified from the Alexion pharmacovigilance database (December 21, 2018 through December 31, 2025). Descriptive statistics were used to summarize patient demographics, treatment patterns, and pregnancy outcomes.
resultsThe 354 pregnancy cases with ≥ 1 dose of ravulizumab exposure that were identified include all reported cases: PNH (n = 160), aHUS (n = 72), no condition reported (n = 45), gMG (n = 38), NMOSD (n = 34), and other (n = 5). Among cases with pregnancy outcome data (n = 106), the ravulizumab exposure included full-pregnancy exposure (17.0%), ravulizumab-to-eculizumab switch during pregnancy (24.5%), and incomplete exposure details reported (58.5%). Pregnancy outcomes included 68 live births (64.2%), 29 spontaneous abortions (27.4%), 3 fetal deaths (2.8%), and 6 elective terminations (5.7%). For a nested subset of 44 post-marketing cases with detailed ravulizumab exposure data, as well as information on pregnancy outcomes (PNH [n = 26], aHUS [n = 10], gMG [n = 3], NMOSD [n = 3], and not reported [n = 2]), live births were reported in 32 cases (72.7%), spontaneous abortions in 11 cases (25.0%), and elective terminations in 1 case (2.3%).
conclusionThis post-marketing analysis provides real-world insights on ravulizumab exposure during pregnancy and suggests favorable outcomes and no unexpected safety signals similar to eculizumab. The findings may support shared decision-making between prescribers and patients when considering the ravulizumab use during pregnancy. An ongoing global observational ravulizumab pregnancy study will further inform the safety profile (NCT06312644).
Indexed as
Identifiers
42853533What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.